W
WAVEMAN · COMPANY
JAZZ · Jazz Pharmaceuticals Plc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

JAZZ

Jazz Pharmaceuticals plc
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001232524
FORM 144 · 16☆ WATCH
INSIDER NET · 180D
-$31.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
377
13F, latest reported quarter
REVENUE GROWTH
+4.9%
XBRL, annual
NET MARGIN
-8.3%
CONVERSIONS · 180D
7
codes C/M, not in net · $8.9M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$31.0M over 180 days
-$24.2M over 90 days
below 92% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
377 funds added or opened last quarter
more than 95% of Pharma & Biotech
REVENUE
+4.9% year over year
more than 54% of Pharma & Biotech
MARGIN
-8.3% net margin
more than 57% of Pharma & Biotech
BUYBACKS
$125.0M repurchased, FY to 2025-12-31
more than 68% of Pharma & Biotech
SHORT
5.2% of shares outstanding short · 5.3 days to cover · settled 2026-07-31
more than 56% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$31.0M across 7 people in 180 days.
377 funds added or opened positions in the latest 13F quarter, of 647 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +90.4%
+90.4%12M
-3%+32%+67%+102%2025-092025-102025-122026-032026-052026-072026-09 2025-11-26 · COZADD BRUCE C sold $6.8M2025-11-26 · COZADD BRUCE C sold $5.4M2026-08-27 · Iannone Robert sold $4.9M2026-08-27 · Iannone Robert sold $4.5M2026-08-27 · Iannone Robert sold $4.5M2026-02-26 · Patil Neena M sold $3.2M2026-02-26 · Patil Neena M sold $3.0M2026-08-27 · Iannone Robert sold $2.8M2026-08-27 · Iannone Robert sold $2.3M2026-02-26 · Patil Neena M sold $2.2M2026-05-28 · Pearce Samantha sold $1.6M2026-08-03 · COZADD BRUCE C sold $1.5M2025-11-18 · COZADD BRUCE C sold $1.5M2025-11-26 · COZADD BRUCE C sold $1.5M2026-09-01 · COZADD BRUCE C sold $1.5M2026-07-01 · COZADD BRUCE C sold $1.4M2026-06-01 · COZADD BRUCE C sold $1.4M2026-05-01 · COZADD BRUCE C sold $1.2M2025-11-17 · Iannone Robert sold $1.2M2026-02-26 · Henderson Mary Elizabeth sold $1.0M2025-11-18 · COZADD BRUCE C sold $1.0M2025-11-18 · Winningham Rick E sold $994.7K2025-11-18 · Carr Patricia sold $955.9K2025-12-05 · Carr Patricia sold $770.4K2026-04-01 · COZADD BRUCE C sold $700.8K2026-02-26 · Patil Neena M sold $682.0K2026-05-22 · Winningham Rick E sold $662.1K2026-02-27 · RIEDEL NORBERT G sold $655.7K2025-11-18 · COZADD BRUCE C sold $609.4K2025-11-20 · McSharry Heather Ann sold $607.1K2026-03-03 · COZADD BRUCE C sold $587.9K2026-02-26 · Patil Neena M sold $553.5K2025-10-03 · COZADD BRUCE C sold $490.0K2026-03-03 · COZADD BRUCE C sold $487.0K2026-05-22 · McSharry Heather Ann sold $482.0K2026-04-01 · COZADD BRUCE C sold $437.6K2025-09-02 · COZADD BRUCE C sold $390.0K2025-09-02 · COZADD BRUCE C sold $381.7K2025-12-09 · Henderson Mary Elizabeth sold $379.4K2026-02-26 · Patil Neena M sold $342.3K2026-05-28 · Patil Neena M sold $282.5K2026-06-10 · Patil Neena M sold $278.2K2026-09-01 · Bruce C Cozadd filed to sell $1.5M2026-08-31 · COZADD BRUCE C filed to sell $612.8K2026-08-31 · Cook Jennifer E. filed to sell $857.6K2026-08-31 · ENRIGHT PATRICK G filed to sell $857.6K2026-08-31 · Hamill Laura filed to sell $857.6K2026-08-31 · Henderson Mary Elizabeth filed to sell $942.0K2026-08-31 · RIEDEL NORBERT G filed to sell $857.6K2026-08-31 · LOVE TED W filed to sell $373.4K2026-08-31 · Winningham Rick E filed to sell $857.6K2026-08-31 · McSharry Heather Ann filed to sell $857.6K2026-08-31 · Smith Mark Douglas filed to sell $857.6K2026-08-31 · Kennedy Patrick filed to sell $857.6K2026-08-27 · ROBERT IANNONE filed to sell $19.2M2026-08-07 · ORiordan Anne filed to sell $882.3K2026-08-03 · Bruce C Cozadd filed to sell $1.5M2026-07-01 · Bruce C Cozadd filed to sell $1.4M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $31.0M sold by insiders over 180 days, 377 funds added last quarter, $33.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Jazz Pharmaceuticals plc insiders sold a net $31.0M of stock across 251 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
COZADD BRUCE C
Director
SELL
2026-09-01
6,000.0
$1.5M
Iannone Robert
EVP, Global Head of R&D & CMO
SELL
2026-08-27
18,187.0
$4.5M
Iannone Robert
EVP, Global Head of R&D & CMO
SELL
2026-08-27
11,423.0
$2.8M
Iannone Robert
EVP, Global Head of R&D & CMO
SELL
2026-08-27
18,113.0
$4.5M
Iannone Robert
EVP, Global Head of R&D & CMO
SELL
2026-08-27
19,639.0
$4.9M
251 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 246 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
5,968,603.0 sh
$1.4B
FMR LLC
4,609,326.0 sh
$1.1B
VANGUARD PORTFOLIO MANAGEMENT LLC
3,036,213.0 sh
$731.6M
VANGUARD CAPITAL MANAGEMENT LLC
2,729,650.0 sh
$657.8M
Capital World Investors
2,697,610.0 sh
$650.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Bruce C Cozadd
FILED 2026-09-01
$1.5M
COZADD BRUCE C
FILED 2026-08-31
$612.8K
Cook Jennifer E.
FILED 2026-08-31
$857.6K
ENRIGHT PATRICK G
FILED 2026-08-31
$857.6K
Hamill Laura
FILED 2026-08-31
$857.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Saratoga Health & Biotechnology Fund
$615.9K POSITION · AS OF 2026-02-28
5.3%
LIVE OAK HEALTH SCIENCES FUND
$2.6M POSITION · AS OF 2026-04-30
5.3%
ROCK OAK CORE GROWTH FUND
$552.0K POSITION · AS OF 2026-04-30
4.3%
Invesco Pharmaceuticals ETF
$11.4M POSITION · AS OF 2026-04-30
3.4%
iShares U.S. Pharmaceuticals ETF
$32.1M POSITION · AS OF 2026-03-31
3.2%
DEAN MID CAP VALUE
$7.4M POSITION · AS OF 2026-03-31
3.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 92 registered trials, 24 still enrolling or running — a status change here is dated weeks before the press release
17
Phase 1
5 ACTIVE
19
Phase 2
5 ACTIVE
35
Phase 3
6 ACTIVE
7
Phase 4
2 ACTIVE
9
Not applicable
4 ACTIVE
5
Multi-phase
2 ACTIVE
What changed recently
Child and Adolescent Registry for Participants With Narcolepsy
2026-09-03 · Recruiting → Unknown
—
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Pa
2026-09-02 · Completion moved 2026-07-31 → 2026-09-30
Phase 3
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Jazz Pharmaceuticals, Inc. Political Action Committee
CYCLE 2026 · $194K SPENT
$144.4K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · Renee D. Gala
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2024
$15.5M
$17.3M
$4.7M
-25%
-7%
2023
$15.3M
-$2.5M
$4.2M
-25%
-6%
2022
$17.3M
$26.3M
$5.0M
-3%
-10%
2021
$15.7M
$4.9M
$4.5M
-23%
+0%
2020
$12.6M
$19.6M
$4.1M
+11%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$4.3B$4.1B$3.8B$3.7B
OPERATING INCOME$-430.2M$716.6M$578.6M$-65.5M
NET INCOME$-356.1M$560.1M$414.8M$-224.1M
EPS (DILUTED)-5.848.656.10-3.58
OPERATING CASH FLOW$1.4B$1.4B$1.1B$1.3B
CASH$1.4B$2.4B$1.5B$881.5M
LONG-TERM DEBT$4.3B$6.1B$5.1B$5.7B
BUYBACKS$125.0M$311.4M$269.8M$54.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →